When the tumor acquired resistance to FOLFIRI with radiographic evidence of tumor progression and rising MAFs of BRAF, TP53, and SMAD (Fig 1), there was no evidence of MET amplification (Fig 2A). This evidence concerns the gene TP53 and neoplasm.